Clinical Trials Logo
  1. Home
  2. Oral Squamous Cell Carcinoma
  3. NCT04543266
  4. Details
NCT04543266 Clinical Trial

Predicting Metastatic Oral Squamous Cell Carcinomas With Molecular Biomarkers Using Machine Learning

Oral Squamous Cell Carcinoma Clinical Trial

Official title:
Predicting Metastatic Oral Squamous Cell Carcinomas With Molecular Biomarkers Using Machine Learning

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT04543266
Other study ID # UW19-704
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 7, 2020
Est. completion date December 31, 2023

Study information
Verified date November 2019
Source The University of Hong Kong
Contact SW Choi, PhD
Phone +85228590390
Email htswchoi@hku.hk
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Application Management Team:

PI - Siu Wai Choi; email - htswchoi@hku.hk Delegates - Chui Shan Chu; email: sunshine.c@connect.hku.hk FollowUpUsers - Chui Shan Chu; email:sunshine.c@connect.hku.hk

Description:

Eligibility Criteria:

- patients were diagnosed with a baseline disease of oral squamous carcinoma.

Exclusion Criteria:

- N/A

Sample size:

- ~500 subjects

Source of Data:

- The data, such as age and medical records, would be obtained from Hospital Authority Clinical Management System (HACMS)

Statistical analysis:

- machine learning will be applied into analysis plan

Recruitment information / eligibility
Status Recruiting
Enrollment 500
Est. completion date December 31, 2023
Est. primary completion date December 31, 2021
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- patients with oral squamous carcinoma

- received surgery from 1st October 2000 to 1st October 2019

Exclusion Criteria:

N/A

Study Design

Related Conditions & MeSH terms

Intervention

Procedure:
• Surgery
Resection of tumors

Locations
Country Name City State
Hong Kong The University of Hong Kong Hong Kong

Sponsors (1)
Lead Sponsor Collaborator
The University of Hong Kong

Country where clinical trial is conducted

Hong Kong, 

Outcome
Type Measure Description Time frame Safety issue
Primary The primary outcomes of the study are metastasis and recurrent disease These outcomes will be entered as the dependent variables into the machine learning model Baseline of OSCC
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06438939 - NBI for Early Diagnosis of OPMD/OSCC N/A
Recruiting NCT05024383 - Dissecting the Heterogeneity of Oral Cancer Pain N/A
Recruiting NCT06031337 - Salivary Expression of SOX7 in Oral Squamous Cell Carcinoma: Diagnostic Accuracy Study
Not yet recruiting NCT06174428 - Validity of Viome's Oral/Throat Cancer Test
Recruiting NCT05098119 - Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002) Phase 2
Recruiting NCT05069857 - Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients Phase 2
Not yet recruiting NCT03619304 - Assessment of Anti-cancerous Effect of Green, Roasted and Decaffeinated Coffee on Oral Squamous Cell Carcinoma Cell Line N/A
Active, not recruiting NCT01772706 - Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer N/A
Recruiting NCT05893888 - Safety and Efficacy Study of PRV211 in Subjects With Oral Squamous Cell Carcinoma Phase 1/Phase 2
Recruiting NCT05125055 - Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC Phase 2/Phase 3
Not yet recruiting NCT06055868 - People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity
Not yet recruiting NCT06130007 - A Prospective, Single-arm Phase II Clinical Trial of Tislelizumab Combined With Platinum Doublet Neoadjuvant Therapy to Improve Mandibular Preservation in Resectable Locally Advanced Oral Squamous Cell Carcinoma. Phase 2
Recruiting NCT05798793 - Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma Phase 3
Recruiting NCT02739204 - Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma Phase 2
Completed NCT05708209 - The Long Non Coding MALAT1 as a Potential Salivary Diagnostic Biomarker in Oral Squamous Cell Carcinoma Through Targeting mi RNA 124
Recruiting NCT05862168 - Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial Phase 2
Recruiting NCT05451303 - Detection of Oral and Throat Cancers Using OralViome Cancer Testing System
Recruiting NCT05902455 - Differential Mobility Spectrometry (DMS) Based Oral Tumor Analysis
Not yet recruiting NCT05803915 - Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy Phase 2
Recruiting NCT05791149 - Epigenetic Biomarkers in the Saliva for the Diagnosis of Squamous Cells Carcinoma of the Oral Cavity N/A